The problem is evident no matter where you look: Injectable drugs are in short supply.
What’s less evident is exactly why – or how, precisely, to resolve the problem.
In our next several newsletters, OsoBio will examine why injectable drugs are in short supply, what shortages mean for our industry, and how the regulatory landscape – as well as partner relationships – may change as a result.
We hope to share information and insight – and, in return, we hope you’ll share your own perspective back with us.
Because if there’s anything we're learning from these shortages, perhaps it’s that we all play a part in creating them – just as we all play a part in addressing them.
So I hope to hear from you as we learn from our collective experience about shortages – and work collaboratively to do what’s best for both our industry and the patients we seek to help.